AMYLOIDOSIS ALLIANCE The Voice of Patients

Research

Clinical trials

Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.

Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.

Recruiting and upcoming studies

The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.

Showing 49–60 of 208 trials

Not yet recruitingAL (light chain)

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis (opens on ClinicalTrials.gov)

This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory primary light chain (AL) amyloidosis.The primary…

Study
Interventional (treatment)
Phase
Phase 1
Sponsor
Shenzhen Fosun Kairos Biotechnology Co., Ltd.

Recruiting in: China

NCT07765524Updated 14 August 2026

RecruitingATTR (transthyretin)

ATTR Cardiac Amyloidosis in a Selected Population (opens on ClinicalTrials.gov)

Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy…

Study
Observational (registry, imaging)
Sponsor
Helse Møre og Romsdal HF

Recruiting in: Norway

NCT06458374Updated 12 August 2026

Not yet recruitingATTR (transthyretin)

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) (opens on ClinicalTrials.gov)

The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin…

Study
Interventional (treatment)
Phase
Phase 3
Sponsor
Eidos Therapeutics, a BridgeBio company

No study locations listed yet

NCT07116473Updated 11 August 2026

RecruitingNot specified

Cardiovascular Multimodality Imaging Study (opens on ClinicalTrials.gov)

Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular…

Study
Observational (registry, imaging)
Sponsor
Montefiore Medical Center

Recruiting in: United States

NCT06610019Updated 10 August 2026

RecruitingATTR (transthyretin)

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant (opens on ClinicalTrials.gov)

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates…

Study
Interventional (treatment)
Phase
Phase 3
Sponsor
Eidos Therapeutics, a BridgeBio company

Recruiting in: ArgentinaAustraliaBelgiumBrazil+20

NCT06563895Updated 4 August 2026

RecruitingAL (light chain)

A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). (opens on ClinicalTrials.gov)

The goal of this clinical trial is to learn if teclistamab in combination with daratumumab (Tec-Dara) works to treat newly diagnosed multiple myeloma with…

Study
Interventional (treatment)
Phase
Phase 2
Sponsor
Shanghai Zhongshan Hospital

Recruiting in: China

NCT07638683Updated 3 August 2026

This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.

Search all studies on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 25 September 2026. clinicaltrials.gov

Not sure where to start?

Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.

Find an association near you
Contact the Alliance